$183 Million is the total value of Prosight Management, LP's 40 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TNET | New | TRINET GROUP INC | $5,288,400 | – | 78,000 | +100.0% | 2.88% | – |
| OPCH | New | OPTION CARE HEALTH INC | $4,660,881 | – | 154,898 | +100.0% | 2.54% | – |
| HCAT | New | HEALTH CATALYST INC | $3,696,306 | – | 347,724 | +100.0% | 2.02% | – |
| UNH | New | UNITEDHEALTH GROUP INC | $2,650,900 | – | 5,000 | +100.0% | 1.45% | – |
| NTLA | New | INTELLIA THERAPEUTICS INC | $2,516,127 | – | 72,116 | +100.0% | 1.37% | – |
| CSII | New | CARDIOVASCULAR SYS INC DEL | $1,987,376 | – | 145,916 | +100.0% | 1.08% | – |
| OSH | New | OAK STR HEALTH INC | $1,806,840 | – | 84,000 | +100.0% | 0.98% | – |
| New | GALAPAGOS NVcall | $1,775,200 | – | 40,000 | +100.0% | 0.97% | – | |
| New | SEAGEN INCcall | $1,542,120 | – | 12,000 | +100.0% | 0.84% | – | |
| LFST | New | LIFESTANCE HEALTH GROUP INC | $1,429,315 | – | 289,335 | +100.0% | 0.78% | – |
| MORF | New | MORPHIC HLDG INC | $1,148,886 | – | 42,949 | +100.0% | 0.63% | – |
| AZYO | New | AZIYO BIOLOGICS INC | $786,310 | – | 185,014 | +100.0% | 0.43% | – |
| BMEA | New | BIOMEA FUSION INC | $690,476 | – | 81,907 | +100.0% | 0.38% | – |
| BBIO | New | BRIDGEBIO PHARMA INC | $678,386 | – | 89,027 | +100.0% | 0.37% | – |
| GOSS | New | GOSSAMER BIO INC | $575,050 | – | 265,000 | +100.0% | 0.31% | – |
| New | THE ONCOLOGY INSTITUTE INC | $454,676 | – | 275,561 | +100.0% | 0.25% | – | |
| New | TENAYA THERAPEUTICS INC | $215,197 | – | 107,063 | +100.0% | 0.12% | – | |
| PSNL | New | PERSONALIS INC | $116,163 | – | 58,668 | +100.0% | 0.06% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALDEYRA THERAPEUTICS INC | 19 | Q2 2023 | 6.2% |
| ALBIREO PHARMA INC | 18 | Q4 2022 | 9.2% |
| MEIRAGTX HOLDINGS PLC | 18 | Q3 2023 | 6.3% |
| KEZAR LIFE SCIENCES INC | 17 | Q3 2023 | 8.2% |
| ARENA PHARMACEUTICALS INC | 16 | Q4 2021 | 8.2% |
| IOVANCE BIOTHERAPEUTICS INC | 16 | Q1 2022 | 7.7% |
| CENTENE CORP DEL | 16 | Q3 2023 | 5.3% |
| CUE BIOPHARMA INC | 14 | Q1 2023 | 5.6% |
| PROTHENA CORP PLC | 13 | Q3 2023 | 13.6% |
| ZIMMER BIOMET HOLDINGS INC | 13 | Q3 2021 | 9.8% |
View Prosight Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| EXICURE, INC. | February 14, 2022 | 2,426,508 | 2.2% |
| Aldeyra Therapeutics, Inc. | February 12, 2021 | 908,488 | 2.3% |
| Teligent, Inc. | February 14, 2020 | 1,484,527 | 2.8% |
| Cidara Therapeutics, Inc. | February 14, 2019 | 245,764 | 0.9% |
| Eiger BioPharmaceuticals, Inc.Sold out | February 14, 2019 | 0 | 0.0% |
| Millendo Therapeutics, Inc. | February 14, 2019 | 256,739 | 2.0% |
| OvaScience, Inc. | October 26, 2018 | 1,991,100 | 5.6% |
| CHIMERIX INC | February 13, 2018 | 1,478,519 | 3.1% |
| Harvard Apparatus Regenerative Technology, Inc. | February 12, 2016 | 184,360 | 1.4% |
View Prosight Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-03 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-02 |
| 13F-HR | 2023-11-14 |
View Prosight Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.